期刊文献+

齐拉西酮与氯丙嗪对首发精神分裂症患者心电图及认知功能的影响比较 被引量:2

Effects of ziprasidone and chlorpromazine on the ECG and cognitive function of patients with first episode of schizophrenia
原文传递
导出
摘要 目的:探讨齐拉西酮与氯丙嗪对首发精神分裂症患者心电图及认知功能的影响。方法将90例首发精神分裂症患者采用数字表法随机分为两组,每组各45例,其中对照组给予氯丙嗪,观察组口服齐拉西酮,比较两组临床疗效及治疗前后认知功能和心电图结果。结果观察组和对照组治疗后阳性和阴性症状量表(PANSS)评分分别为(57.78±4.16)分和(58.43±4.33)分,均较治疗前的(72.62±4.66)分和(72.39±4.87)分显著减少(t=7.15、7.46,均P<0.05),但两组间差异无统计学意义(均P>0.05);观察组治疗后威斯卡星卡片分类测试(WCST)总测验次数、持续错误数和数字化消测验(CT)失误率分别为(73.32±5.08)、(40.35±4.15)和(12.72±2.00)%,均较治疗前的(86.43±5.58)、(67.72±4.26)和(21.02±2.33)%及对照组的(84.32±5.16)、(65.82±4.25)和(20.05±2.20)%显著减少( t=6.84、7.21、7.85、7.52、8.21、8.12,均P<0.05);WCST分类完成数和CT净分值分别为(5.32±0.40)和(125.83±11.65)分,均较治疗前的(3.41±0.38)和(102.82±10.72)分及对照组的(3.52±0.39)和(108.37±10.24)分显著增加( t=6.72、7.11、7.01、7.53,均P<0.05);观察组治疗后心电图异常发生率为22.22%,显著低于对照组的55.56%(χ2=11.02,P<0.05)。结论齐拉西酮与氯丙嗪治疗首发精神分裂症疗效相当,但齐拉西酮可明显改善患者认知功能,且对患者心电图影响小,临床安全性高。 Objective To investigate the effects of ziprasidone and chlorpromazine on the ECG and cognitive function of patients with first episode of schizophrenia .Methods According to the digital table ,90 patients with first-episode schizophrenia were divided into two groups ,45 cases in each group .The control group was given chlorproma-zine,while the observation group received oral ziprasidone .Clinical efficacy,cognitive function and ECG results were compared before and after treatment .Results The PANSS scores of the study group and the control group were (57.78 ±4.16) points and (58.43 ±4.33) points after treatment,which were significantly lower than (72.62 ± 4.66)points and (72.39 ±4.87)points before treatment (t=7.15,7.46,all P〈0.05),but the differences were not significant between the two groups (all P〉0.05).The total number of tests of WCST ,continuous errors and CT error rate in study group after treatment were (73.32 ±5.08),(40.35 ±4.15) and (12.72 ±2.00)%,which were signif-icantly lower than (86.43 ±5.58),(67.72 ±4.26) and (21.02 ±2.33)%before treatmemt and (84.32 ±5.16), (65.82 ±4.25) and (20.05 ±2.20)%in the control group(t=6.84,7.21,7.85,7.52,8.21,8.12,all P〈0.05). WCST categories completed and the number of CT net scores were (5.32 ±0.40) and (125.83 ±11.65) points, which were significantly higher than (3.41 ±0.38) and (102.82 ±10.72) points before treatment and (3.52 ± 0.39) and (108.37 ±10.24)points in the control group,the differences were statistically significant (t=6.72,7.11, 7.01,7.53,all P〈0.05).The incidence rate of abnormal ECG in study group was 22.22% after treatment,which was significantly lower than 55.56% in the control group(χ2 =11.02,P〈0.05).Conclusion Ziprasidone and chlorpromazine have a equivalent efficacy in the treatment of first-episode schizophrenia ,but ziprasidone can signifi-cantly improve cognitive function and has little effect on ECG ,it is safe.
作者 孙宏斌
出处 《中国基层医药》 CAS 2014年第15期2283-2284,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 精神分裂症 齐拉西酮 氯丙嗪 心电描记术 认知 Schizophrenia Ziprasidone Chlorpromazine Electrocardiography Cognition
  • 相关文献

同被引文献23

  • 1中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版(精神障碍分类)[J].中华精神科杂志,2001,34(3):184-188.
  • 2Grimaldi-Bensouda L, Rouillon F, Astruc B, etal. Does long-act- ing injectable risperidone make a difference to the real-life treat- ment of schizophrenia Results of the Cohort for the General study of Schizophrenia ( CGS ) [ J ]. Schizophr Res, 2012,134 ( 2-3 ) : 187-194. DOI: 10. 1016/j. schres, 2011.10. 022. Epub 2011 Nov 30.
  • 3Hor K, Taylor M. Suicide and schizophrenia:a systematic review of rates and risk factors[J]. J PsychopharmaCol,2010,24(4 Sup- pl) :81-90. DOI: 10. 1177/1359786810385490.
  • 4Nikolaus S, Hautzel H, Mtlller HW. Neurochemical dysfunction in treated and nontreated schizophrenia -a retrospective analysis of in vivo imaging studies [ J ]. Rev Neumsei, 2014,25 ( 1 ) : 25-96. DOI: 10.1515/revneuro-2013-0063.
  • 5Huang M, Panos JJ, Kwon S, et al. Comparative effect of lurasi- done and blonanserin on cortical glutamate, dopamine, and acetyl- choline efflux:role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1 A partial agonism [ J ]. J Neurochem ,2014, 128(6) :938-949. DOI: 10. llll/jne. 12512. Epuh 2013 Nov 14.
  • 6Juruena MF, de Sena EP, de Oliveira IR. Sertindole in the man- agement of schizophrenia [ J ].J Cent Nerv Syst Dis, 2011,17 (3) :75-85. DOI:10.4137/JCNSD. $5729. Print 2011.
  • 7Masri B, Salahpour A, Didriksen M, et al. Antagonism of dopa- mine I)2 receptor/be-arresfin 2 interaction is a common property of clinically effective antipsychotics[ J]. Proc Natl Acad Sci USA, 2008, 105 (36): 13656-13661. DOI: 10. I073/pnas. 0803522105.
  • 8Rummel-Kluge C,Komossa K,Schwarz S,et al. HeM-to-head com- parisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenla:a systematic review and meta-anal- ysis [ J ]. Schizophr Res,2010,123 (2/3) :225-233. DOI: 10. 1016/j. schres. 2010.07.012.
  • 9Gupta A, Dadheech G, Yadav D, et al. Metabolic issues in schizo- phrenic patients receiving antipsychotic treatment [ J ]. Indian J Clin Biochem, 2014,29 ( 2 ) : 196-201. DOI: 10. 1007/s12291- 013-0415-z.
  • 10Cordes J, Kabl KG, Werner C, et al. Clomipramine-induced serum pmlaetin as a marker for semtonin and dopamine turnover: results of an open label study[ J]. Eur Arch Psychiatry Clin Neuresci, 2011,261 (8) :567-573. DOI:10. 1007/s00406-011-020I-y.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部